We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.
- Authors
Egilman, Alexander C.; Kesselheim, Aaron S.; Sarpatwari, Ameet; Rome, Benjamin N.
- Abstract
This document presents a study on the impact of skinny-label generic competition on Medicare Part D spending from 2015 to 2021. Skinny-label generics are generic drugs that are approved for a subset of the indications of the brand-name drug. The study found that skinny-label generic competition saved Medicare approximately $14.6 billion during this period. The savings were highest for drugs such as Crestor, Lyrica, and Gleevec. The study suggests that skinny-label generics can improve patient access to lower-cost medications and recommends reinforcing the skinny-label pathway to encourage timely generic competition.
- Subjects
MEDICARE Part D; GENERIC drugs; DRUG labeling; PATENT suits; EVEROLIMUS
- Publication
Annals of Internal Medicine, 2024, Vol 177, Issue 6, p833
- ISSN
0003-4819
- Publication type
Article
- DOI
10.7326/M23-3212